Current therapeutic trends for tinnitus cure and control - a scoping review

Vatsal Chhaya MSc*1, Divya Patel MPharm², Shamik Mehta MS(ENT)³,

Jignesh Rajvir MS(ENT)⁴ Vinodkumar Jhinjhuwadia MBBS⁵, Pranshuta Sehgal

MS(ENT)⁶, Kapil Khambholja MPharm, PhD⁷

- 1. Senior Executive, Medical Writing and Real-World Evidence, Genpro Research Pvt. Ltd., Vadodara, Gujarat.
- 2. Trainee Medical Writer, Genpro Research Pvt. Ltd., Vadodara, Gujarat.
- 3. Consultant & ENT Surgeon, Ahmedabad, Gujarat.
- 4. Consultant & ENT surgeon, Gandhinagar, Gujarat
- 5. Consulting family physician, Rajkot, Gujarat.
- 6. Senior Resident (ENT), Hindu Rao Hospital, New Delhi.
- 7. Vice President, Genpro Research Inc., Boston, USA.

*Correspondence to: Vatsal Chhaya Senior Executive Medical Writing and RWE Genpro Research Inc. vatsal.chhaya@genproresearch.com

Abstract

Objectives - The absence of high-level evidence about treatment approaches in tinnitus

has eluded the clinical community from arriving at the consensus to date. This could be

partially attributable to a limited number of trials. The objective of the present scoping

review was to check updates in existing knowledge about tinnitus management and

provide recommendations for further research and practice.

- **Design -** Scoping review with *Population, Concept, and Context (PCC)* framework. • Review question(s) for our study were:
- 1. Is there any knowledge update from the published evidence on the treatment of tinnitus after the scoping review on tinnitus by Makar S et al. 2017?
- 2. Are there any therapies existing that do not focus on habituation but target the root cause of tinnitus?

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 3. Which pharmacological interventions are used in the treatment of tinnitus?
- Methods The database of our literature search included PubMed, Joanna Briggs Evidence synthesis, Cochrane Library, Scopus, and Google Scholar. We included full-text original articles (randomized controlled trials (RCTs), systematic reviews (SLRs), or meta-analyses) published in the *English* language between 2010-2021. We included only studies that included interventions to treat patients without any focus on the patient's habituation or natural adaptation. We excluded reviews, case studies, observational studies, and anecdotal evidence.
- **Patient and Public Involvement** Being a secondary data-based analysis, our study did not directly involve any patient.
- **Results** Of 20 included records, 11 SLRs and nine RCTs were found. Nonpharmacological interventions included transcranial magnetic- (TMS) (four studies) and direct current stimulation (tDCS) (three studies), vagus nerve stimulation (VNS) (one study), and hearing aid or combined amplification and sound generator (two studies); however, despite causing moderate improvement in tinnitus severity, neither of these interventions reached statistical significance. Pharmacological interventions included AM-101(two studies), anticonvulsants (one study), and antidepressants (one study) with insufficient strength to establish the efficacy of either. Also, a specific extract of the *Ginkgo Biloba* (EGb 761®) plant demonstrated a reduction in tinnitus severity (1 study). No studies included actionable insights on the quality of life (QoL) outcomes.
- **Conclusions** Despite the lack of actionable evidence for tDCS and rTMS like therapies, their curative potential cannot be overlooked. Hence, it is recommended to conduct large-scale trials on similar interventions. Also, aspects like patient-reported outcomes (PROs) in tinnitus.

Keywords: Tinnitus, management, scoping review, hearing aids, transcranial direct current stimulation, Severity of illness index

Protocol registration

The protocol was registered in the open science framework registry (OSF) (registration *DOI:10.17605/OSF.10/R8D39*)

Introduction

The clinical care pathway is a major deterministic factor for better patient outcomes. Conventionally, it is decided based on clinical acumen. However, with the increasing clinical inclination towards evidence-based medicine, the best available evidence and patient values and preferences have been also strongly recommended to consider while determining treatment course. Nevertheless, there are a few clinical conditions with a blurry picture in terms of standard clinical care, including Tinnitus. Tinnitus is a clinical condition in which patients hear a ringing sound in their ears, impacting their quality of life. It may be referred to as "*phantom auditory perception*"[1] with a variety of sounds including – hissing, buzzing, clicking, chirping, ringing, whistling, or cricket-like sound, which can be intermittent or continuous.

Tinnitus is not a disease but a symptom of various underlying otological (noise-induced hearing loss, otosclerosis, Meniere's disease), neurological (multiple sclerosis, head injury), and cardiovascular disorders (atherosclerosis),[2] affecting an estimated 10-15% of the adult population globally.[3] Epidemiologic data shows tinnitus prevalence as 15% in the USA,[4] 14.2% in Europe,[5] 13.2% in the UK,[6] and 14.5% in China.[7]

Tinnitus, regardless of its clinical type, can be distressing and may deteriorate the patient's quality of life.[8] It may interfere with routine activities. Individuals suffering from tinnitus might experience anxiety, depression, irritability, sleep cycle disturbances, poor concentration, pain, and even suicidal thoughts in extreme cases.[9] Even though the exact cause and mechanism for tinnitus are not known, it may be associated with age-related hearing loss, middle ear infection, trauma, a loud work environment with noises, or ototoxic drugs like NSAIDs (non-steroidal anti-inflammatory drugs), antibiotics, chemotherapeutic agents.[10–12] The lack of a proper mechanism makes it difficult to manage or treat the condition.

Despite several systematic literature reviews (SLRs) published on the efficacy of various clinical interventions to cure tinnitus, there is no food and drugs administration (FDA)approved, gold standard treatment or drug for tinnitus to date.[13] Several treatment pathways are identified through anecdotal evidence including but not limited to cognitive-behavioral therapy (CBT), tinnitus retraining therapy (TRT), biofeedback, psychoeducation or counseling, hearing aids, electrical stimulation, antidepressants, anticonvulsants, dietary supplements.[2,11,14–16] However, their implications in practice can be debated due to a lack of high-level evidence. In addition, combination therapies have shown promising potential not only in terms of relief from tinnitus but also improvement in the holistic health of the patient.[17–19]

Given such inconclusive evidence from the published SLRs on the efficacy/effectiveness of various clinical interventions for tinnitus treatment, it is difficult to build the practice consensus. Instead, a novel research concept has gained immense interest especially from a policy perspective, known as "scoping review (ScR). It is a typical variant of the traditional systematic review, where rigorous specific attention towards any single interventions' efficacy and safety is replaced by collation of evidence in a comprehensive and informative manner.[20] Although there are several scoping reviews published on Tinnitus in the past,[21–28] to the best of authors' knowledge, no research provided a holistic overview of the treatment options likely to be recommended in the actual treatment of tinnitus; however, no information about its protocol registration was found. Also, mapping of reported content in the same ScR with the PRISMA-ScR checklist was not possible due to the later release of the revised checklist in 2020.[21]

The objective of the present scoping review was to check updates in existing knowledge about tinnitus management and provide recommendations for further research and practice. We addressed the following research questions:

- 1. Is there any knowledge update from the published evidence on the treatment of tinnitus after the scoping review on tinnitus by Makar S et al. 2017?
- 2. Are there any therapies existing that do not focus on habituation but target the root cause of tinnitus?
- 3. Which pharmacological interventions are used in the treatment of tinnitus?

Material and Methods

Protocol registration

The initial version of the protocol for this study was registered at the open science framework registry (OSF), registration *DOI: 10.17605/OSF.IO/R8D39*

Study selection criteria

Study Design and Search Filters

Although being a scoping review, full-text SLRs, meta-analyses, and randomized controlled trials (RCTs) in *English* were included to maintain the quality of evidence with the highest scientific hierarchy. We excluded review articles, case reports, case series, cross-sectional studies, and observational studies. Focusing on the recency of the data, records published before 2010, or records not published in *English* if any.

Population

We included studies on patients with tinnitus regardless of its type. No age or gender-related restrictions were applied as per the protocol. Tinnitus was defined as the sound in ears with or without any identifiable clinical cause.[1] It included both subjective and objective types, where the former refers to the tinnitus perceived only by the sufferer and the latter refers to the perception of tinnitus by both the examiner and sufferer through an objective assessment of the condition.

Concept

We included the records containing information about the efficacy and safety profile of pharmacological, non-pharmacological, or miscellaneous interventions for the treatment of tinnitus. Studies including details about secondary outcomes like effect on tinnitus-induced distress, anxiety, sleep disturbance, or depression were also included if any. Studies assessing habituation/natural adaptation-oriented therapy such as TRT, CBT, masking were excluded. Nevertheless, studies including on multidisciplinary approach to treat tinnitus were considered regardless of the presence of therapies with the cognitive outcome(s).

Context

We included studies without applying restrictions on geographic regions.

Search Strategy

A preliminary search was performed on PubMed to identify the relevant search terms used in publications related to tinnitus. Following this step, a detailed search strategy was developed which included the following databases – Cochrane, PubMed, Scopus, and Google Scholar. The PubMed-based search was performed using an AI-powered tool named VOODY (*Genpro Research Inc.*). The search strategy used for the Cochrane database can be accessed from Appendix-1.

Additionally, a targeted search was performed from additional sources like Google, American Tinnitus Association, British Tinnitus Association, All Indian Institute of Speech and Hearing (AIISH), and Joanna Briggs Institute Evidence Synthesis. Also, an exclusive targeted search for tinnitus-related scoping review was performed using the VOODY.

Two independent reviewers (DP and PS) performed the screening and selection of retrieved records. Any discrepancy regarding inclusion was resolved by mutual agreement or a consenting third reviewer (KK).

Data charting

The data charting instrument/template was prepared and piloted using three articles by PS and VC. Following necessary modifications post-pilot work, DP and VC performed the charting. The extraction items included: author, year of publication, study type, type of tinnitus, population demographic details, concept (intervention used, outcome measures), context (study region). Outcome measures were categorized into primary (tinnitus severity, loudness, annoyance, distress) and secondary (QoL, HRQoL, depression, anxiety) outcomes. SM and JR cross-verified the extracted data with the help of source records. Any disagreement was resolved by mutual discussion or consensus from the third reviewer (VJ). The charted data were synthesized using the tabulation method by DP and verified by KK and JR.

Patient and Public Involvement:

Being a secondary data-based analysis, our study did not directly involve any patient.

Results

Study selection

The literature search based on the final search strategy yielded 4148 records from the aforementioned multiple databases including 754 duplicate records. Following de-duplication, 270 records were sought for full-text retrieval. However, due to 184 conference abstracts, only 86 records were shortlisted to assess eligibility. After excluding records that did not meet eligibility criteria for various reasons, total 20 records were included in the final analysis. A detailed description of the study selection process is shown in Figure 1 (PRISMA-ScR flow diagram).

Study characteristics

The population in the included studies belonged to the age group ≥ 18 years. A higher proportion of males compared to females was observed from the charted data.[29–32] Studies on both types of tinnitus patients (acute and chronic) were included. The patients with Chronic tinnitus were further categorized as subjective, non-pulsatile, unilateral, bilateral, and idiopathic types.

Tinnitus Severity Measurement Tools

The majority of the studies used Tinnitus Handicap Inventory (THI)[30,32–39] and Tinnitus Handicap Questionnaire (THQ).[32,38,40,41] Other tools used for assessment of tinnitus outcome included Tinnitus Functional Index (TFI),[29,34] Visual-Analog Scale (VAS),[34,36,42] Beck Depression Inventory (BDI),[32,38,39] Tinnitus Reaction Questionnaire (TRQ),[32,38] Clinical Global Impression (CGI),[36] Tinnitus Severity Index (TSI).[39,43] One study each used Pittsburgh Sleep Quality Index (PSQI)[39] to assess sleep disturbance and Hamilton Depression Rating Scale (HDRS)[38] to assess depression.

Interventions

The interventions included three major categories: non-pharmacological (ten studies),[29,30,32–34,36,37,42–44] pharmacological (five studies),[31,40,41,45,46] and miscellaneous (five studies).[35,38,39,47,48] Non-pharmacological interventions, specifically

stimulation techniques (rTMS, tDCS, VNS) described reduced tinnitus loudness and severity in 14%-64% patients, depending region applied on the and polarity (anode/cathode).[30,32,36,42,43] Furthermore, 78% patients had reduced tinnitus annoyance while using hearing aids, as obtained by one study.[37] Pharmacological and miscellaneous interventions such as zinc, melatonin, anti-depressant, anti-convulsant, AM-101 (NMDA receptor antagonist), and Ginkgo biloba extract, were able to achieve surrogate effects e.g., reduction in tinnitus-specific depression, improved sleep disturbance; however, inconclusive.[31,35,39–41,46,47] The charted data with study-specific details is depicted in Appendix-2.

Discussion

The complex nature of tinnitus has deterred researchers and clinicians from studying the root cause or mechanisms, rendering the patients' suffering intact. Moreover, a limited number of research studies with the majority of them showing zero to non-significant clinical benefit causes an evidence gap with a lesser likelihood of access to novel therapies for tinnitus patients. To overcome these challenges, we adopted an emerging method known as "*Scoping Review*" to create an evidence map about tinnitus therapies known so far. This scoping review intended to check if any updated information that published after a similar study by Makar S et al.2017.[21] The purpose behind such an objective was to connect the missing dots in the trajectories of tinnitus care with a holistic approach. Also, a broad spectrum of information covering both HICs and LMICs introduced comprehensiveness in the data charting process. Secondly, recency of the information was ensured through limiting studies between the timeframe 2010-2021 (from last 10 years). This also helped to understand current vistas in the therapeutic management of tinnitus as well as the progress directions for tinnitus research.

Our review included only SLRs, meta-analyses, and RCTs – the topmost parts of the evidence pyramid. The interventions for tinnitus from our findings could be broadly put in three major categories: i) Non-pharmacological, ii) Pharmacological, and iii) Miscellaneous. Majority of evidence corresponded to non-pharmacological interventions for tinnitus, indicating continued research interest for innovative therapeutic modalities for tinnitus.[49] However, it is even more important to consider the inherent risk associated with such seemingly promising invasive therapies like tDCS.[50] The studies from our review reported transient treatment effects from the use of various stimulation techniques, which was corroborated by the similar short-term reduction in tinnitus loudness after application of tDCS as reported in scoping reviews by Elyssa et al.[25] and Shekhawat et al.[28] Another deterministic factor for technologies like rTMS that determines the efficacy of the respective stimulation technique includes the

consideration of technical parameters. A systematic review by Schoisswohl S et al.[51] evaluated the same and recommended exhaustive reporting of rTMS technical parameters for better outcomes.

On the other side, pharmacological interventions focused on secondary outcomes like effects on depression, anxiety, and sleep disturbance. None of the reviewed studies included any pharmacological intervention directly targeting the root cause of tinnitus, partially attributable to a lack of sound knowledge about potential mechanisms.

Miscellaneous therapies studied in our review also included herbal preparation - *Ginkgo biloba*. Interestingly, no safety-related information was researched for the study on *Ginkgo Biloba* despite proven efficacy outcomes. Also, only a specific extract (EGb 761®) was successful in demonstrating its efficacy in tinnitus over the other *Ginkgo Biloba* preparations due to poor methodology.[47] This may serve as a strong impetus to strengthen the methodological framework for miscellaneous therapies in tinnitus research. Another emerging trend that could be seen amongst clinicians includes multidisciplinary tinnitus management. However, no evidence has been found to date that could advocate such a practice.

A scoping review by Makar et al.[21] described the interventions with intended cognitive effect on tinnitus, including counseling, tinnitus masking, TRT, CBT, relaxation, and attention diversion in tinnitus patients. Complementing the same, our study described the role of nonpharmacological as well as adjuvant pharmacological treatment modalities which may play little to moderate role in tinnitus management. Additionally, unlike previous scoping review(s) which either focused on interventions with surrogate effect or specific to individual interventions,[22–28] our study demonstrated uniqueness by providing comprehensive yet simple information. In other words, our scoping review data charting included every detail about study interventions, severity scales, outcomes, and recommendations from respective

studies. Thus, it helped better understand the methodological quality of the included records. Albeit it is to be noted that scoping review does not emphasize on critical appraisal of collected evidence.

Despite a well-devised search strategy, our study remained to demonstrate any actionable insights based on collected evidence. This could be partially attributable to limited access to subscription journals. Besides, although our study aimed to include both HIC and LIC, the majority of our data belonged to HICs[29,30,32,42,43,45,46], indicating an evidence gap in developing countries to be bridged using even robust search strategy with broadened access. We also acknowledge several significant changes to the registered protocol version on the OSF platform, which were deemed mandatory to be implemented during project execution (Appendix-3).

To conclude, strong recommendation for the effectiveness of any therapy in tinnitus is still far from reality. Invasive stimulation techniques have demonstrated moderate efficacy when applied to a specific region of tinnitus patients. Existing pharmacological interventions focus only on cognitive outcomes and no drug has been discovered to target the root cause of tinnitus to date. Multidisciplinary, combinational therapy or polypharmacy approach has gained recent clinical attention despite the low quality of evidence in the light of patient values and preferences. Therefore, the authors recommend considering patient-reported outcomes in tinnitus as the potential research area given the lack of QoL measures in current evidence.

References:

- 1 Jastreboff PJ. Phantom auditory perception (tinnitus): mechanisms of generation and perception. *Neuroscience Research* 1990;**8**:221–54. doi:https://doi.org/10.1016/0168-0102(90)90031-9
- 2 Tang D, Li H, Chen L. Advances in Understanding, Diagnosis, and Treatment of Tinnitus. Advances in experimental medicine and biology 2019;**1130**:109–28. doi:10.1007/978-981-13-6123-4_7
- Henry JA, Reavis KM, Griest SE, *et al.* Tinnitus: An Epidemiologic Perspective.
 Otolaryngologic Clinics of North America 2020;**53**:481–99.
 doi:10.1016/j.otc.2020.03.002
- 4 Understanding the Facts | American Tinnitus Association. https://www.ata.org/understanding-facts#nhnes (accessed 4 May 2021).
- 5 Axelsson A, Ringdahl A. Tinnitus--a study of its prevalence and characteristics. *British journal of audiology* 1989;**23**:53–62. doi:10.3109/03005368909077819
- 6 The number of people living with tinnitus in the UK higher than previously thought -British Society of Audiology. https://www.thebsa.org.uk/the-number-of-people-livingwith-tinnitus-in-the-uk-higher-than-previously-thought/ (accessed 4 May 2021).
- Xu X, Bu X, Zhou L, *et al.* An epidemiologic study of tinnitus in a population in Jiangsu Province, China. *Journal of the American Academy of Audiology* 2011;**22**:578–85. doi:10.3766/jaaa.22.9.3
- 8 Yetiser S, Tosun F, Satar B, *et al.* The role of zinc in management of tinnitus. *Auris Nasus Larynx* 2002;**29**:329–33. doi:10.1016/S0385-8146(02)00023-8
- Adoga AA, Obindo TJ. The Association Between Tinnitus and Mental Illnesses.
 Mental Disorders Theoretical and Empirical Perspectives Published Online First: 16 January 2013. doi:10.5772/52755
- 10 Demographics | American Tinnitus Association. https://www.ata.org/understanding-facts/demographics (accessed 4 May 2021).
- 11 Langguth B, Kreuzer PM, Kleinjung T, et al. Tinnitus: causes and clinical management. *The Lancet Neurology* 2013;**12**:920–30. doi:10.1016/S1474-4422(13)70160-1
- 12 Henry JA, Roberts LE, Caspary DM, *et al.* Underlying mechanisms of tinnitus: review and clinical implications. *Journal of the American Academy of Audiology* 2014;**25**:5–22; quiz 126. doi:10.3766/jaaa.25.1.2
- 13 Drug Therapies | American Tinnitus Association. https://www.ata.org/managing-yourtinnitus/treatment-options/drug-therapies (accessed 2 Jun 2021).
- Tunkel DE, Bauer CA, Sun GH, *et al.* Clinical practice guideline: Tinnitus.
 Otolaryngology Head and Neck Surgery (United States). 2014;151:S1–40.
 doi:10.1177/0194599814545325
- 15 Chronischer Tinnitus. http://www.awmf-leitlinien.de, (accessed 5 May 2021).

- 16 Langguth B. Treatment of tinnitus. *Current Opinion in Otolaryngology and Head and Neck Surgery* 2015;**23**:361–8. doi:10.1097/MOO.00000000000185
- 17 Jastreboff MM. Sound therapies for tinnitus management. 2007. 435–40. doi:10.1016/S0079-6123(07)66042-7
- 18 Henry JA, Frederick M, Sell S, *et al.* Validation of a Novel Combination Hearing Aid and Tinnitus Therapy Device. *Ear & Hearing* 2015;**36**:42–52. doi:10.1097/AUD.00000000000093
- Baguley D, McFerran D, Hall D. Tinnitus. *The Lancet* 2013;**382**:1600–7. doi:10.1016/S0140-6736(13)60142-7
- 20 Sucharew H, Macaluso M. Methods for Research Evidence Synthesis: The Scoping Review Approach. *Journal of hospital medicine* 2019;14:E1–3. doi:10.12788/jhm.3248
- 21 Makar SK, Mukundan G, Gore G. Treatment of tinnitus: A scoping review. International Tinnitus Journal 2017;**21**:144–56. doi:10.5935/0946-5448.20170027
- 22 Thompson DM, Hall DA, Walker D-M, *et al.* Psychological Therapy for People with Tinnitus: A Scoping Review of Treatment Components. *Ear and hearing* 2017;**38**:149–58. doi:10.1097/AUD.00000000000363
- 23 Shekhawat GS, Searchfield GD, Stinear CM. Role of Hearing Aids in Tinnitus Intervention: A Scoping Review. *Journal of the American Academy of Audiology* 2013;24:747–62. doi:10.3766/jaaa.24.8.11
- Tutaj L, Hoare DJ, Sereda M. Combined Amplification and Sound Generation for Tinnitus: A Scoping Review. *Ear & Hearing* 2018;**39**:412–22. doi:10.1097/AUD.0000000000516
- 25 Elyssa Kok T, Schaette R, Shekhawat GS. Impact of tDCS and HD-tDCS on tinnitus perception: A scoping review. 2021. 225–44. doi:10.1016/bs.pbr.2020.05.002
- 26 Hoare DJ, Adjamian P, Sereda M. Electrical Stimulation of the Ear, Head, Cranial Nerve, or Cortex for the Treatment of Tinnitus: A Scoping Review. *Neural Plasticity* 2016;**2016**:1–15. doi:10.1155/2016/5130503
- Haider HF, Hoare DJ, Costa RFP, *et al.* Pathophysiology, Diagnosis and Treatment of Somatosensory Tinnitus: A Scoping Review. *Frontiers in Neuroscience* 2017;11. doi:10.3389/fnins.2017.00207
- 28 Shekhawat GS, Stinear CM, Searchfield GD. Modulation of Perception or Emotion? A Scoping Review of Tinnitus Neuromodulation Using Transcranial Direct Current Stimulation. *Neurorehabilitation and Neural Repair* 2015;29:837–46. doi:10.1177/1545968314567152
- 29 Folmer RL, Theodoroff SM, Casiana L, *et al.* Repetitive Transcranial Magnetic Stimulation Treatment for Chronic Tinnitus. *JAMA Otolaryngology–Head & Neck Surgery* 2015;**141**:716. doi:10.1001/jamaoto.2015.1219

- 30 Tyler R, Cacace A, Stocking C, *et al.* Vagus Nerve Stimulation Paired with Tones for the Treatment of Tinnitus: A Prospective Randomized Double-blind Controlled Pilot Study in Humans. *Scientific Reports* 2017;**7**:11960. doi:10.1038/s41598-017-12178-w
- 31 Staecker H, Morelock M, Kramer T, *et al.* Safety of Repeated-Dose Intratympanic Injections with AM-101 in Acute Inner Ear Tinnitus. *Otolaryngology–Head and Neck* Surgery 2017;157:478–87. doi:10.1177/0194599817711378
- 32 Formánek M, Migaľová P, Krulová P, *et al.* Combined transcranial magnetic stimulation in the treatment of chronic tinnitus. *Annals of clinical and translational neurology* 2018;**5**:857–64. doi:10.1002/acn3.587
- 33 Sereda M, Xia J, el Refaie A, *et al.* Sound therapy (using amplification devices and/or sound generators) for tinnitus. *Cochrane Database of Systematic Reviews* Published Online First: 27 December 2018. doi:10.1002/14651858.CD013094.pub2
- 34 Londero A, Bonfils P, Lefaucheur JP. Transcranial magnetic stimulation and subjective tinnitus. A review of the literature, 2014–2016. *European Annals of Otorhinolaryngology, Head and Neck Diseases* 2018;**135**:51–8. doi:10.1016/j.anorl.2017.12.001
- 35 Person OC, Puga ME, da Silva EM, et al. Zinc supplementation for tinnitus. Cochrane Database of Systematic Reviews Published Online First: 23 November 2016. doi:10.1002/14651858.CD009832.pub2
- Forogh B, Mirshaki Z, Raissi GR, *et al.* Repeated sessions of transcranial direct current stimulation for treatment of chronic subjective tinnitus: a pilot randomized controlled trial. *Neurological Sciences* 2016;**37**:253–9. doi:10.1007/s10072-015-2393-9
- 37 dos Santos GM, Bento RF, de Medeiros IRT, *et al.* The Influence of Sound Generator Associated With Conventional Amplification for Tinnitus Control: Randomized Blind Clinical Trial. *Trends in Hearing* 2014;**18**:233121651454265. doi:10.1177/2331216514542657
- 38 Hoare DJ, Kowalkowski VL, Kang S, *et al.* Systematic review and meta-analyses of randomized controlled trials examining tinnitus management. *The Laryngoscope* 2011;**121**:1555–64. doi:10.1002/lary.21825
- 39 Miroddi M, Bruno R, Galletti F, *et al.* Clinical pharmacology of melatonin in the treatment of tinnitus: a review. *European Journal of Clinical Pharmacology* 2015;**71**:263–70. doi:10.1007/s00228-015-1805-3
- 40 Baldo P, Doree C, Molin P, *et al.* Antidepressants for patients with tinnitus. *Cochrane Database of Systematic Reviews* Published Online First: 12 September 2012. doi:10.1002/14651858.CD003853.pub3
- Hoekstra C el, Rynja SP, van Zanten GA, *et al.* Anticonvulsants for tinnitus. *Cochrane Database of Systematic Reviews* Published Online First: 6 July 2011. doi:10.1002/14651858.CD007960.pub2

- 42 Garin P, Gilain C, van Damme J-P, *et al.* Short- and long-lasting tinnitus relief induced by transcranial direct current stimulation. *Journal of neurology* 2011;**258**:1940–8. doi:10.1007/s00415-011-6037-6
- 43 Mennemeier M, Chelette KC, Allen S, *et al.* Variable changes in PET activity before and after rTMS treatment for tinnitus. *The Laryngoscope* 2011;**121**:815–22. doi:10.1002/lary.21425
- 44 Yuan T, Yadollahpour A, Salgado-Ramírez J, *et al.* Transcranial direct current stimulation for the treatment of tinnitus: a review of clinical trials and mechanisms of action. *BMC Neuroscience* 2018;**19**:66. doi:10.1186/s12868-018-0467-3
- 45 Fornaro M. Tinnitus psychopharmacology: A comprehensive review of its pathomechanisms and management. *Neuropsychiatric Disease and Treatment* 2010;:209. doi:10.2147/NDT.S10361
- van de Heyning P, Muehlmeier G, Cox T, *et al.* Efficacy and Safety of AM-101 in the Treatment of Acute Inner Ear Tinnitus—A Double-Blind, Randomized, Placebo-Controlled Phase II Study. *Otology & Neurotology* 2014;**35**:589–97. doi:10.1097/MAO.0000000000268
- von Boetticher A. Ginkgo biloba extract in the treatment of tinnitus: a systematic review. *Neuropsychiatric disease and treatment* 2011;7:441–7. doi:10.2147/NDT.S22793
- 48 Zenner H-P, Delb W, Kröner-Herwig B, *et al.* A multidisciplinary systematic review of the treatment for chronic idiopathic tinnitus. *European Archives of Oto-Rhino-Laryngology* 2017;**274**:2079–91. doi:10.1007/s00405-016-4401-y
- 49 McFerran DJ, Stockdale D, Holme R, *et al.* Why Is There No Cure for Tinnitus? *Frontiers in Neuroscience* 2019;**13**. doi:10.3389/fnins.2019.00802
- 50 Folmer RL, Theodoroff SM, Martin WH, *et al.* Experimental, Controversial, and Futuristic Treatments for Chronic Tinnitus. *Journal of the American Academy of Audiology* 2014;**25**:106–25. doi:10.3766/jaaa.25.1.7
- 51 Schoisswohl S, Agrawal K, Simoes J, *et al.* RTMS parameters in tinnitus trials: a systematic review. *Scientific Reports* 2019;**9**:12190. doi:10.1038/s41598-019-48750-9

Data availability: Data sharing is not applicable. All data are from publicly available resources. The same could be accessed through the links/information given in the bibliography.

Patient consent for publication: Not required

Contributors: VC and KK conceptualized the topic and prepared a detailed methodology to perform the review. DP and PS collected the data. DP and VC drafted the manuscript and performed data synthesis and analysis. VJ and PS performed the data validation. KK supervised

the whole project. JR, SM, PS, and KK gave editorial support and reviewed the manuscript. All the authors read and approved the final manuscript.

Conflicts of Interest: The authors for this paper have no conflicts of interest to declare.

Funding: This study received no funding from any agency in public, commercial or not-for-profit sectors.

Appendix-1: Final search strategy

Database searched: PubMed, Scopus, Cochrane, Google Scholar, JBI Evidence synthesis.

Eligibility Criteria

Inclusion Criteria:

- Systematic reviews, meta-analysis, and clinical trials in last 10 years
- Studies containing information about Tinnitus and its management therapy(ies)

Exclusion Criteria:

The review will exclude the following:

- Review article, observational studies, qualitative notes, case studies, case reports
- Studies not focusing on tinnitus and its management therapy(ies)
- Studies older than 2010 (1 Feb 2021)
- Studies for which full-text not available
- Studies not published in English

Example Search strategy (Cochrane):

#1 MeSH descriptor: [Tinnitus] this term only and with qualifier(s): [diagnosis - DI, drug
 therapy - DT, epidemiology - EP, physiopathology - PP, radiotherapy - RT, surgery - SU, therapy - TH]

#2 multidisciplinary AND tinnitus AND outcome

#3 stimulation AND tinnitus AND invasive

Search date: 1 Feb 2021

Time frame: last 10 years (2010-2021)

Appendix-2: Charted data from included studies

				POPULATIO	ON		CONCEPT					CONTEXT	
Sr. No	Primar y Author	Publication year	Evidence type	Population	Type of tinnitus	Study period	Intervention			Outcomes		Study region	Remarks
							Non- pharmacological	Pharmacological	Miscellaneous	Primary outcome	Secondary outcome		
1	Garin et al.	2011	RCT (sham controlled, double- blinded)	n = 20 Age = 18-80 y	chronic tinnitus	42 days	Stimulation: Transcranial direct current stimulation (tDCS); anodal, cathodal, sham Intensity: 1mA Duration: 20 min for each session Session: 3 sessions after 2 weeks interval	No information found		Effect on tinnitus intensity: VAS score improvement in 35% patients (anodal tDCS). Non- significant changes through cathodal tDCS	Effect on depression and anxiety: No significant difference	Europe	Both anodal and cathodal tDCS could be studied for their potential to trigger plastic changes, reflecting in tinnitus perception.
2	Forogh et al.	2015	RCT (sham controlled, double- blinded)	n = 22 Age =≥18y	chronic tinnitus	14 days	Stimulation: tDCS; anodal, cathodal, sham Current intensity: 2 mA Duration: 20 min Follow-up period: 14 days after the last session	No information found		Effect on tinnitus loudness and distress: Reduction in 3 patients (anodal tDCS) and 2 patients (sham) at 14 days follow-up. VAS reduction: not significant for both the groups Safety outcomes: worsening of symptoms in 36.4% of patients in the experimental group	No information found	Middle East	Property of tDCS to induce neuromodulatio n could be studied in depth with further research before it is practiced; neuroimaging could aid informed decision making due to its objective nature

				POPULATIO	ON		CONCEPT					CONTEXT	
Sr. No	Primar y Author	Publication year	Evidence type	Population	Type of tinnitus	Study period	Intervention			Outcomes		Study region	Remarks
							Non- pharmacological	Pharmacological	Miscellaneous	Primary outcome	Secondary outcome		
3	Yuan et al.	2018	Systemati c Review	No information found	No informatio n found	No inform ation found	Stimulation: tDCS current intensity: 1-2 mA, session: single or repeated for 15-20 min Target for Stimulation: Dorsolateral prefrontal cortex (DLPFC) and auditory cortex (AC) regions	No information found		Effect on Tinnitus Percept via Neuromodulation: moderate to a significant reduction	Effect on tinnitus- related depression and anxiety: clinical improveme nt when tDCS applied to bifrontal DPFLC region	Global	Given the heterogeneity of studies, tDCS can be recommended as an adjunct/comple mentary therapy for non tractable tinnitus
4	Menne meier et al.	2011	RCT (sham- controlled, crossover)	n = 21. Age: 28-75 y	chronic bilateral tinnitus	7 days	Stimulation: Repetitive transcranial magnetic stimulation (rTMS); active, sham Frequency: 1Hz Duration: 30 minutes session for 5 days	No information found		Effect on tinnitus loudness: 43% of patients (active rTMS) reduced tinnitus loudness as reflected in Visual Analogue Ratings of Tinnitus Loudness(VARL), however, this could not correlate with PET scan findings.	No information found	USA	Use of PET scan is questionable to target rTMS

				POPULATIO	ON		CONCEPT Outcomes					CONTEXT	
Sr. No	Primar y Author	Publication year	Evidence type	Population	Type of tinnitus	Study period	Intervention			Outcomes		Study region	Remarks
							Non- pharmacological	Pharmacological	Miscellaneous	Primary outcome	Secondary outcome		
5	Folmer et al.	2015	RCT (sham controlled)	n = 64 M:80% F:20%	chronic tinnitus	182 days	Stimulation: rTMS(active rTMS or placebo rTMS Session: 2000 pulses per session for 10 days Frequency: 1 Hz Follow-up: 1,2,4,13,and 26 weeks after last session	No information found		Effect on tinnitus severity: significant reduction in TFI (active rTMS) at 26th week (effect size = 0.92 for experimental vs. 0.18 for placebo group) p=0.007	No information found	Europe	Although sustained improvements were observed, larger studies are required for effectively practising rTMS
6	Forman ek	2018	RCT (sham controlled, double- blinded)	n = 53. M:62% F:38%	chronic subjective unilateral or bilateral nonpulsati le primary tinnitus	No inform ation found	Stimulation: rTMS(group 1); Sham stimulation(Group 2); Frequency: DPFLC : 25Hz,300 pulses, 80% resting motor threshold(RMT) on left side Primary AC: 1 Hz, 1000 pulses; 110% RMT on both sides Duration: 5 consecutive days Follow-up: After 1 month and 6 months from the previous session	medicament therapy: GFinkgo Biloba extract (group 3)		Effect on Tinnitus Severity score: Improvement in 63% (rTMS), 58% (sham group), and 28% (medicament group) after 1 month Improvement in 25%-29% for medicament therapy Effect on THQ, BDI, TRQ: non- significant improvement Safety outcome: Temporal side effects (Headache)	No information found	Europe	No significant effect of bilateral low-frequency rTMS of the primary auditory cortex and high- frequency stimulation of the left dorsolateral prefrontal cortex was demonstrated

				POPULATIO	DN		CONCEPT					CONTEXT	ſ
Sr. No	Primar y Author	Publication year	Evidence type	Population	Type of tinnitus	Study period	Intervention			Outcomes		Study region	Remarks
						N	Non- pharmacological	Pharmacological	Miscellaneous	Primary outcome	Secondary outcome		
7	Londero et al.	2018	Systemati c Review	No information found	Subjective tinnitus	No inform ation found	Stimulation: rTMS; with or without Sham stimulation group Range of frequency: 1-20 Hz Range of number of stimuli: 200- 4000 per session	No information found		Effect on Tinnitus Severity (not exclusively mentioned though) Subjective measures: Tinnitus Handicap Inventory, Tinnitus Functional Index, and anxiety, depression, or quality of life questionnaires) or visual analog scales (VAS); objective measures: intracortical activation/inhibition, PET-scan	No information found	Global	Low frequency(1Hz) r-TMS may demonstrate clinical efficacy for the short term when applied on tempo-parietal regions; high degree of heterogeneity
8	Tyler et al.	2017	RCT (double- blinded)	n = 30 M:83% F:17%	chronic sensorineu ral tinnitus	84 days	Stimulation: Vagus nerve stimulation (VNS) Paired VNS vs. Unpaired VNS during 2.5 hours	No information found		Effect on tinnitus severity: >20% improvement in 50% participants (VNS paired) after 42 days (p=0.0012) compared to that in 28% participants from the control group using THI. improvement in 56% participants after 12 weeks in paired VNS vs. 28% in control. Safety Outcome: Mild AE well	No information found	USA	90% of participants kept the device and the rest had the device explanted

				POPULATIO	ON		CONCEPT					CONTEXT	[
Sr. No	Primar y Author	Publication year	Evidence type	Population	Type of tinnitus	Study period	d			Outcomes		Study region	Remarks
							Non- pharmacological	Pharmacological	Miscellaneous	Primary outcome	Secondary outcome		
										tolerated (Iatrogenic vocal cord paralysis)			
9	Sereda et al.	2018	Systemati c Review	n = 590, >=18 years	acute or chronic subjective idiopathic tinnitus	No inform ation found	Devices: Hearing Aid (HA) only vs. Sound Generator only; Combinational hearing aid (CHA) vs. HA only	No information found		Effect on Tinnitus Symptom Severity HA vs. SG - Clinically significant reduction with no statistical difference in THI for both groups at 3,6, and 12 months CHA vs HA - no difference in THI/Tinnitus Functional Index between both groups (standardized mean difference -0.15, 95% confidence interval -0.52 to 0.22; Safety outcomes: No safety outcomes were assessed in any of included studies	Not assessed (Depression , Anxiety, Health- related QoL, tinnitus intrusivenes s, ability to ignore, concentrati on, quality of sleep, and sense of control)	Global	No recommendatio ns were made on the superiority and inferiority of any of the interventions over the others due to the low quality of evidence

				POPULATIO	ON			CONCEPT				CONTEXT	
Sr. No	Primar y Author	Publication year	Evidence type	Population	Type of tinnitus	Study period	Intervention			Outcomes		Study region	Remarks
							Non- pharmacological	Pharmacological	Miscellaneous	Primary outcome	Secondary outcome		
10	Dos Santos et al.	2014	RCT (blinded)	n = 49	No informatio n found	No inform ation found	Devices used: HA, CHA Usage criteria: minimum 8 hours a day Time period for assessment: after 3 months of device usage	No information found		Effect on tinnitus annoyance: Reduction in 62.5% patients (HA+SG) and 78% patients (HA group) however not significant p=0.24.	No information found	Brazil	Superiority over using CHA and HA was not found
11	Fornaro and Martino	2010	Systemati c Review	No information found	Subjective tinnitus	No inform ation found	No information found	Drug: Psychopharmacolo gical agents (Antidepressants, Sedative Hypnotics, Glutamatergic Compounds, Antipsychotics, Unassessed Potential Targets)		No specific information is available except general claims without reference.	No information found	Europe	Poor quality of evidence
12	Hoekstr a et al.	2011	Systemati c Review	n = 453	chronic tinnitus	No inform ation found	No information found	Drug: Anti- convulsant (gabapentin, carbamazepine, flunarizine and lamotrigine)		Effect on Tinnitus Severity: Pooled effect with gabapentin vs placebo for THI standardized mean difference did not show any significance (SMD 0.07, 95% CI -0.26 to 0.40).	Self- assessment of Tinnitus Severity by patients (any positive effect and total eradication of tinnitus annoyance): Risk difference	Global	Presence of high risk of bias in given evidence; small effect (of doubtful clinical significance) has been demonstrated in case of anticonvulsants for tinnitus

				POPULATIO	ON		tudy Intervention Outcomes					CONTEXT	
Sr. No	Primar y Author	Publication year	Evidence type	Population	Type of tinnitus	Study period	Intervention			Outcomes		Study region	Remarks
							Non- pharmacological	Pharmacological	Miscellaneous	Primary outcome	Secondary outcome 14% (95% CI 6%-225) and 4% (95% CI - 2% to 11%)		
13	Baldo et al.	2012	Systemati c Review	n = 610	No informatio n found	No inform ation found	No information found	Drug: Anti- depressants (amitriptyline, nortriptyline and trimipramine)		Effect on tinnitus severity and disability: No significant changes in THQ score due to antidepressants Safety outcomes: common side-effects such as dry mouth, sexual dysfunction, sedation	Quality of life (QoL): Improved QoL reported for trazodone (atypical anti- depressant), however not statistically significant Effect on depressive symptoms: Nor- triptyline showed to reduce depression in Hamilton. Other studies showed non- significant	Global	Given the inconclusive poor evidence, further research for use of antidepressants in tinnitus is warranted

				POPULATIO	DN			CONCEPT				CONTEXT	
Sr. No	Primar y Author	Publication year	Evidence type	Population	Type of tinnitus	Study period				Outcomes		Study region	Remarks
							Non- pharmacological	Pharmacological	Miscellaneous	Primary outcome	Secondary outcome change/not	-	
											assessed		
14	P. vAN De Heynin g et al.	2014	RCT (placebo- controlled, double- blinded)	n = 248 Age 18-65 y	acute inner-ear tinnitus	90 days	No information found	Drug: AM-101 Dose: low dose- 0.27 mg/ml, high dose- 0.81 mg/ml; or placebo Duration: 3- consecutive days Assessment: Day 0,1,2,7,30, and 90		Effect on minimum masking level (MML): No significant change Effect on tinnitus loudness, annoyance, and sleep difficulties: significant improvement in the high-dose group (p<0.001) Safety outcomes: non-fatal serious adverse events in the high-dose group were that led to discontinuation of study drug administration.	No information found	Europe	Given the demonstrated safety profile, AM-101 could be a good agent warranting further research to cure tinnitus

				POPULATIO	DN			CONCEPT				CONTEXT	
Sr. No	Primar y Author	Publication year	Evidence type	Population	Type of tinnitus	Study period	Intervention			Outcomes		Study region	Remarks
							Non- pharmacological	Pharmacological	Miscellaneous	Primary outcome	Secondary outcome		
15	Staecke r et al.	2017	RCT (double- blinded, multisite)	n = 343 M:77% F:23% Age = ≥18 y	acute tinnitus	84 days	No information found	Drug: AM-101 (3 intratympanic doses with 0.87 mg/mL per dose		Effect on hearing threshold: transient increase in < 7% patients Safety outcome: mild AE in 4-6% patients (ear pain, discomfort) with the experimental group; SAE that led to discontinuation of patients in trials - subjective worsening of hearing, otitis externa/inflammatio n of ear canal, otitis media, and nausea	No information found	North America, Europe, Asia	The repeated dose can be used for 3 to 5 days for acute tinnitus
16	Hoare et al.	2011	Systemati c Review	No information found	No informatio n found	No inform ation found	Intervention (matching our ScR scope): Hearing Aids and Sound Enrichment Therapy	Antidepressants, Anxiolytics,	Melatonin(Neur ohormone Sedative)	No specific information is available due to the old study.	No information found	Global	No recommendatio ns on the therapeutic potential of any therapy could be made
17	Zenner et al.	2017	Systemati c Review	No information found	chronic idiopathic tinnitus	No inform ation found	Not applicable	Not applicable	Multidisciplinar y	No specific information found	No information found	Global	Lack of strong, actionable evidence from this review

				POPULATIO	DN		CONCEPT					CONTEXT	
Sr. No	Primar y Author	Publication year	Evidence type	Population	Type of tinnitus	Study period				Outcomes		Study region	Remarks
							Non- pharmacological	Pharmacological	Miscellaneous	Primary outcome	Secondary outcome		
18	Boettich er	2011	Systemati c Review	n = 1199		No inform ation found	No information found		Drug: Ginkgo Biloba extract (EGb 761®)	Effect on tinnitus severity: Not all but trials investigating EGb 761 showed significant improvement, found superior to placebo	No information found	Global	Efficacy of other <i>Ginkgo</i> <i>Biloba</i> preparations cannot be proven (might be attributable to methodological bias)
19	Miroddi et al.	2015	Systemati c Review	n = 356	Subjective tinnitus	No inform ation found	Not applicable	Melatonin combined with sulpiride, combined with sulodexide Dose: 3mg daily oral administration	Melatonin; melatonin alone,	No pooled estimate available on THI and Pittsburgh Sleep Quality Index (PSQI)	No information found	Global	Despite clinical efficacy is demonstrated, the generalizability of findings and practice recommendatio ns are questionable due to biased evidence




Figure 1 PRISMA flow diagram for scoping reviews